Virus News and Research

Latest Virus News and Research

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.

21 Sep 2010

Childhood obesity linked to common cold virus

A new study has shown that obese children are more prone to carrying a common cold virus than slimmer children. The virus in question is adenovirus 36 and if the link is true then someday new obesity treatments might be tailored to attack the virus to treat or prevent childhood obesity. Childhood obesity affects 17% of American children and adolescents. The report appeared in the journal Pediatrics.

21 Sep 2010

Flu shots, heart attacks and flu prevention guidelines

According to a new British study yearly flu shots may protect against heart attacks, and the earlier in the season a shot is given the greater the protection. Niroshan Siriwardena, a professor of primary and pre-hospital health care at the University of Lincoln said, “The risk of getting a heart attack was reduced by 19 percent for those who had a vaccination in the past year.”

21 Sep 2010

AstraZeneca urges to increase funds for FDA fiscal year 2012 budget

AstraZeneca urged the Obama Administration to increase funding for the Food and Drug Administration's fiscal year 2012 budget by 20 percent to help the agency effectively manage a growing list of complex public health responsibilities.

21 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

H1N1 influenza increases neurological complications in children: Study

A recent study by researchers at the University of Utah determined that the 2009 pandemic influenza A (H1N1) caused a higher rate of neurological complications in children than the seasonal flu. The most common complications observed were seizures and encephalopathy.

20 Sep 2010

Adenovirus exposure may cause obesity in children: Study

The emerging idea that obesity may have an infectious origin gets new support in a cross-sectional study by University of California, San Diego School of Medicine researchers who found that children exposed to a particular strain of adenovirus were significantly more likely to be obese.

20 Sep 2010

Researchers discover HIV-1 resists AZT drug

Rutgers researchers have discovered how HIV-1, the virus that causes AIDS, resists AZT, a drug widely used to treat AIDS. The scientists, who report their findings in Nature Structural & Molecular Biology, believe their discovery helps researchers understand how important anti-AIDS treatments can fail and could help AIDS researchers develop more effective treatment for the disease.

20 Sep 2010

Male circumcision shown to help prevent HIV transmission

According to a new study published in the Medical Journal of Australia, male circumcision can be seen as a “surgical vaccine” in the fight against heterosexual HIV transmission. The study based on spread of the virus in Africa showed that there was a reduced rate of transmission in regions where male circumcision was the norm.

19 Sep 2010

PositiveID prepares to commence exchange offer to acquire control of DIGA

PositiveID Corporation commented today on Digital Angel Corporation's response to the Company's proposal to acquire all of the outstanding common stock of DIGA through a merger transaction. Prior to the commencement of trading on September 16th, PositiveID made a firm offer to purchase all of the outstanding shares of DIGA's common stock at an exchange ratio of .67 shares of PositiveID for each share of DIGA, representing a 60 percent premium to DIGA's average closing price for the 20 trading days ending on September 14th.

18 Sep 2010

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

CytoGenix, Inc. today announced that it has initiated the process of testing CytoGenix's novel liner DNA technology on ferrets, with the expectations of a positive result, furthering the development of the vaccine candidate.

18 Sep 2010

Proposal by WHO to eliminate AIDS in South Africa is flawed, model shows

In 2008, Reuben Granich and his colleagues at the World Health Organization published a paper in the medical journal The Lancet that proposed a new strategy for combating HIV in South Africa, a country staggered by the virus, with as much as 18 percent of the population estimated to be infected.

18 Sep 2010

Simian immunodeficiency virus is at least 32,000 to 75,000 years old

An ancestor of HIV that infects monkeys is thousands of years older than previously thought, suggesting that HIV, which causes AIDS, is not likely to stop killing humans anytime soon, finds a study by University of Arizona and Tulane University researchers.

17 Sep 2010

Media reporting can reduce impact of infectious disease outbreaks

At the first sign of a disease pandemic, public health officials should begin strongly communicating about the extent of the outbreak and the steps that can be taken by the public to avoid infection. That's the recommendation of two mathematical biologists who have modified the most widely used infectious disease transmission model to account for the impact of news media coverage.

17 Sep 2010

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company focused on the development of innovative vaccine products, announced today that it has initiated the first clinical trial for its bivalent intramuscular (IM) norovirus vaccine candidate, marking the fourth human clinical trial in the Company's norovirus virus-like particle (VLP) vaccine program.

17 Sep 2010

FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program) to fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Alpha 1 Antitrypsin Deficiency (AAT), a genetic disease known to result in serious lung and/or liver disease.

17 Sep 2010

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic resistant infections, delivered four poster presentations on its Aganocide compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.

16 Sep 2010

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

Renal research consortia receives two grants for translational research from DKF

The Dutch Kidney Foundation (DKF) awards two Consortium Grants of 1,5 million euro to renal research consortia to concentrate on translational research.

16 Sep 2010